Chromogranin A staining as a biomarker for prostate adenocarcinoma
As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.
NSAID use inversely related to prostate cancer incidence and mortality
Based on a meta-analysis reported in BMC Medicine, NSAID use is associated with a decreased risk of prostate cancer (OR=0.92 [total] and 0.81 [advanced]) and prostate cancer-specific mortality (HR=0.86 [total] and 0.81 [advanced]).
Water restriction improves nocturia
As reported in the International Journal of Urology, daytime/night-time water restriction significantly improves nocturia in patients with urine production ≥ 30 mL/kg.